

Mexico is making proactive and systematic strides towards shaping the future of the pharmaceutical industry within the country and ambitiously across the entire region.
The “Estrategia de Certidumbre Regulatoria 2022-2030” (Regulatory Certainty Strategy) was recently presented by COFEPRIS. This well-defined strategy ultimately aims to enhance access to therapies in Latin America. This strategy recognizes the need for local market growth and emphasizes the importance of fostering interconnections within the region, across the continent, and globally.
The Mexican edition of the forum highlights investment as a crucial catalyst for promising growth, elucidates the investment sector’s interests and concerns, and provides proactive measures to navigate the upcoming COFEPRIS-defined scenario effectively.
Who will
you meet?
More than:
Participants
Companies
HCPs
Patients
Academy
Investors
Institutions
Associations
Service Providers
Government Agencies
Industry Executives from Latam
- Biosimilars
- Biobetters
- Biotechnology
- Biotherapeutics
- Analytical science
- Regulatory compliance
- Quality Control
- Clinical immunology
- Scientific Affairs
- Pharmacovigilance
- Research
- Regulatory
- Business Development
- Marketing
Previous Speaker Board

Jose Juarez
Biopharma Market Leader

Rodolfo Landa
Biopharma Market Leader

Jorge Ortiz Palomino
Managing Director

Brendan Bradley
Business Development Manager

Fabricio Carneiro de Oliveira
General Manager

Angelica Meneses Acosta
Research Professor

Eduardo Valencia Rodríguez
CEO

Orlando Aguirre
Market Access & Pricing, Institutional Sales, Government Affairs & Policy HEAD

Oriana Liceth Niño Trejos
Bioprocess Coordinator

Ernesto Martínez-Rosas
Sr. Technical Application Specialist

Sarfaraz Niazi
Adj. Professor

Miguel Angel Abad Hernandez
Rheumatologist

Lucas Filgueira Risso
Site Manager

Juan Luis Fuentes
Region Head of Ethics, Risk & Compliance

Octavio Tonatiuh Ramirez Reivich
Director

Cuauhtémoc Ruiz Toledo
General Secretary

Giroshi Bando
Master Application Specialist

Jean-Edouard Rabier
Global Business Development Director, Business Improvement

Max Sarachaga Osterwalder
Medical Director

Alecio Pimenta
Product Manager for Downstream

Enrique Liñero
Country Head

Maria Concepcion Prieto Yerro
CHMP committee member

German Gonzalez
Clinical Research Manager

Javier Guerra
Regional Head Latam Norte

Daniel Freire
Regional Medical Director - LatAm

Diego Ocampo
Research and Development Vicepresident

Luis Reyes
Head of Quality Assurance Preclinical Unit

Carlos Dominguez
General Manager

Gilberto Castañeda
Researcher

Irma Garcia
Corporate Compliance Officer Mexico & LATAM

Nicolas Estrada
Single-use Customer Applications

Fernando Goicoechea
General Manager LatAm

Cristina Ausin
Scientific Reviewer

Javier Enrique López Aguilar MD
Medical Director

Adriana Hernández Trejo
Deputy Director of medicines and vaccines

Rodrigo Ruíz Ramírez
Head of Country Pharmacovigilance

Carlos Bravo
Field Application Specialist

Josué Bautista
Cluster Safety Lead (NoLA)

Patricia Socualaya Sotomayor
Chief Officer at Biological Product Unit

Juan Pablo Acosta Martinez
Business Development Manager Biosimilars and Senior Application Specialist Purification
Program in 2022
Quality and Integrity of Biopharmaceutical Products Within Production Processes
How to ensure the safety of biotech products within Production processes? Experts sharing their point of view
Commercial Measures for Biosimilars in the LatAm Markets
Commercial strategies and market dynamics to ensure the promotion of biosimilars uptake in Mexico and LatAm
Collaborative: Reference Authorities’ Updates and Actions Towards Regulation for Biosimilars
Stay on top of the newest regulations and tendencies led by reference authorities on biosimilars regulatory frameworks
Biosimilars: Global Innovation and Competitiveness
How to innovate in the biosimilars industry and highly competitive markets?
Sponsors in 2022
Photo Gallery from Previous Events
